EP2099819A4 - Polypeptides multimeres du recepteur fc comprenant un domaine fc modifie - Google Patents

Polypeptides multimeres du recepteur fc comprenant un domaine fc modifie

Info

Publication number
EP2099819A4
EP2099819A4 EP07845376A EP07845376A EP2099819A4 EP 2099819 A4 EP2099819 A4 EP 2099819A4 EP 07845376 A EP07845376 A EP 07845376A EP 07845376 A EP07845376 A EP 07845376A EP 2099819 A4 EP2099819 A4 EP 2099819A4
Authority
EP
European Patent Office
Prior art keywords
multimeric
domain
modified
receptor polypeptides
polypeptides including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07845376A
Other languages
German (de)
English (en)
Other versions
EP2099819A1 (fr
Inventor
Phillip Mark Hogarth
Bruce David Wines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suppremol GmbH
Original Assignee
Suppremol GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2006/001890 external-priority patent/WO2007068047A1/fr
Priority claimed from US11/762,664 external-priority patent/US8354109B2/en
Application filed by Suppremol GmbH filed Critical Suppremol GmbH
Publication of EP2099819A1 publication Critical patent/EP2099819A1/fr
Publication of EP2099819A4 publication Critical patent/EP2099819A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP07845376A 2006-12-13 2007-12-13 Polypeptides multimeres du recepteur fc comprenant un domaine fc modifie Withdrawn EP2099819A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/AU2006/001890 WO2007068047A1 (fr) 2005-12-13 2006-12-13 Polypeptides polymères pour récepteurs fc
US11/762,664 US8354109B2 (en) 2005-12-13 2007-06-13 Multimeric Fc receptor polypeptides
PCT/AU2007/001934 WO2008070927A1 (fr) 2006-12-13 2007-12-13 Polypeptides multimères du récepteur fc comprenant un domaine fc modifié

Publications (2)

Publication Number Publication Date
EP2099819A1 EP2099819A1 (fr) 2009-09-16
EP2099819A4 true EP2099819A4 (fr) 2010-03-17

Family

ID=40961582

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07845376A Withdrawn EP2099819A4 (fr) 2006-12-13 2007-12-13 Polypeptides multimeres du recepteur fc comprenant un domaine fc modifie

Country Status (6)

Country Link
EP (1) EP2099819A4 (fr)
JP (1) JP2010512154A (fr)
BR (1) BRPI0721078A2 (fr)
CA (1) CA2671732A1 (fr)
RU (1) RU2009126545A (fr)
WO (1) WO2008070927A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102718836B (zh) * 2009-04-24 2014-04-16 上海交通大学医学院附属瑞金医院 一种短肽及含有其的免疫抑制剂和应用
EP2492689B8 (fr) * 2011-02-22 2013-12-25 Bernhard-Nocht-Institut für Tropenmedizin Détection des anticorps à l'aide d'un complexe immun amélioré ELISA
CN103911387A (zh) * 2013-01-08 2014-07-09 深圳先进技术研究院 含鼠lgG2a Fc标签的真核表达载体及其构建方法
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
WO2022252131A1 (fr) * 2021-06-01 2022-12-08 Virogin Biotech Canada Ltd. Ace2 multivalente recombinée et ses utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010202A1 (fr) * 2001-07-26 2003-02-06 Medexgen Co. Ltd. Immunoadhesion concatamerique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0406724A (pt) * 2003-01-13 2005-12-20 Macrogenics Inc Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada
CA2555684A1 (fr) * 2004-02-10 2005-08-18 The Austin Research Institute Structures cristallines et modeles pour recepteurs fc et utilisations associees pour la conception et l'identification de composes modulateurs des recepteurs fc
EP1960427B1 (fr) * 2005-12-13 2011-02-23 SuppreMol GmbH Polypeptides polymeres pour recepteurs fc

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010202A1 (fr) * 2001-07-26 2003-02-06 Medexgen Co. Ltd. Immunoadhesion concatamerique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IERINO F L ET AL: "RECOMBINANT SOLUBLE HUMAN FCGAMMARII: PRODUCTION, CHARACTERIZATION AND INHIBITION OF THE ARTHUS REACTION", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, UNITED STATES, vol. 178, no. 5, 1 November 1993 (1993-11-01), pages 1617 - 1628, XP009015491, ISSN: 0022-1007 *
KURUCZ ISTVAN ET AL: "Bacterially expressed human FcgammaRIIb is soluble and functionally active after in vitro refolding", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 75, no. 1, 1 December 2000 (2000-12-01), pages 33 - 40, XP002511480, ISSN: 0165-2478 *
POWELL M S ET AL: "Investigation of FcgammaRIIa dimerization", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 14, no. 6, 20 April 2000 (2000-04-20), pages A960, XP009111142, ISSN: 0892-6638 *
See also references of WO2008070927A1 *

Also Published As

Publication number Publication date
CA2671732A1 (fr) 2008-06-19
RU2009126545A (ru) 2011-01-20
EP2099819A1 (fr) 2009-09-16
BRPI0721078A2 (pt) 2014-10-07
JP2010512154A (ja) 2010-04-22
WO2008070927A1 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
IL248322A0 (en) Variable activin receptor polypeptides and uses thereof
IL248128A0 (en) Stabilized receptor polypeptides and their use
GB2437827B (en) Touch screen element
IL196056A0 (en) Il-8 receptor antagonists
HK1123683A1 (en) Il-8 receptor antagonists il-8
GB0721686D0 (en) Polypeptides
ATE467622T1 (de) Pyrazin-2-carboxamid-derivate als cb2- rezeptormodulatoren
IL202107A0 (en) Fc RECEPTOR BINDING POLYPEPTIDES AND USES THEREOF
IL198990A0 (en) Cb1 receptor modulators
IL194700A0 (en) Il-8 receptor antagonists
EP2099300A4 (fr) Antagonistes de récepteurs de l'il-8
GB0701992D0 (en) Grehlin Receptor Modulators
IL192693A0 (en) Urotensin ii receptor antagonists
IL205749A0 (en) Modified il-4 mutein receptor antagonists
EP2099819A4 (fr) Polypeptides multimeres du recepteur fc comprenant un domaine fc modifie
HK1137353A1 (en) Urotensin ii receptor antagonists ii
GB0623539D0 (en) Polypeptides
ZA200806237B (en) Cannibinoid receptor modulators
EP2032789A4 (fr) Charnière réglable en hauteur
DE602007008589D1 (de) Pyridooxazepin-progesteronrezeptor-modulatoren
GB0705829D0 (en) Waste receptor
GB0712302D0 (en) Chrondroitinase polypeptides
ZA200904663B (en) CB1 receptor modulators
GB0604684D0 (en) Receptor
GB0623399D0 (en) Receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090625

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100215

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100601

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101214